Board of Directors
show all
hide all
Raymond Holdings
Mr. Ward has served on MAP Pharmaceuticals' Board of Directors since February of 2011, bringing over 30 years of experience in the healthcare industry, including 15 years as an operating business leader. Mr. Ward is president of Raymond Holdings, a firm founded in 2011, with activities in venture capital, strategy and transactional advisory services. From 1981 to 2010, Mr. Ward was employed by Medtronic, Inc. and served as Senior Vice President and President of the CardioVascular business of Medtronic Inc., in which role he was responsible for all worldwide operations of the CardioVascular Business including the Coronary, Peripheral, Endovascular, Structural Heart Disease (SHD) and Revascularization and Surgical Therapies (RST) Businesses. Previously, Mr. Ward served as Senior Vice President and President of Medtronic Neurological and Diabetes, with responsibility for the global Neurological, Neurologic Technologies, Diabetes, Gastroenterology and Urology businesses; Vice President and General Manager of the Medtronic Drug Delivery Business; and President of Medtronic Neurological. Mr. Ward is Chairman of the Board of Gillette Children's Specialty Healthcare and also serves on the Board of Surmodics, Inc. He received his Bachelor's Degree in Genetics and Cell Biology in 1981, and his Masters Degree in Toxicology in 1983, both from the University of Minnesota.
Mr. Ward has served on MAP Pharmaceuticals' Board of Directors since February of 2011, bringing over 30 years of experience in the healthcare industry, including 15 years as an operating business leader. Mr. Ward is president of Raymond Holdings, a firm founded in 2011, with activities in venture capital, strategy and transactional advisory services. From 1981 to 2010, Mr. Ward was employed by Medtronic, Inc. and served as Senior Vice President and President of the CardioVascular business of Medtronic Inc., in which role he was responsible for all worldwide operations of the CardioVascular Business including the Coronary, Peripheral, Endovascular, Structural Heart Disease (SHD) and Revascularization and Surgical Therapies (RST) Businesses. Previously, Mr. Ward served as Senior Vice President and President of Medtronic Neurological and Diabetes, with responsibility for the global Neurological, Neurologic Technologies, Diabetes, Gastroenterology and Urology businesses; Vice President and General Manager of the Medtronic Drug Delivery Business; and President of Medtronic Neurological. Mr. Ward is Chairman of the Board of Gillette Children's Specialty Healthcare and also serves on the Board of Surmodics, Inc. He received his Bachelor's Degree in Genetics and Cell Biology in 1981, and his Masters Degree in Toxicology in 1983, both from the University of Minnesota.
Dr. Armer, a co-founder of MAP Pharmaceuticals, has served as Chief Scientific Officer and as a member of the Board of Directors since the Company's inception, and as President and Chief Executive Officer from inception until April 2005. From 1998 to 2003, Dr. Armer served as Vice President of Pulmonary Delivery Systems and later as Chief Scientific Officer at Sheffield Pharmaceuticals, Inc. From 1989 to 1998, Dr. Armer held a series of senior management and product development positions at the Novon Products Group, a division of Warner-Lambert, and Aeroquip Vickers Corporation. Dr. Armer received a Ph.D. in chemical engineering from Tulane University.
Malvern Consulting Group
Ms. Henwood has served as a member of MAP Pharmaceuticals' Board of Directors since June 2004. Ms. Henwood is currently the President of Malvern Consulting Group, an independent pharmaceuticals, biologics and medical devices consulting firm, and serves as the Chief Executive Officer of RecroPharma, Inc., and Garnet BioTherapeutics, Inc. From 1999 to July 2006, Ms. Henwood was President, Chief Executive Officer, and, until May 2005, Chair of the Board of Auxilium Pharmaceuticals, Inc., which she also founded. From 1985 to 1999, Ms. Henwood served as President and Chief Executive Officer of IBAH, Inc., which she had also originally founded as Bio-Pharm Clinical Services, Inc. Ms. Henwood is a member of the board of directors of Alkermes, Inc., and serves as a member of its nominating and governance committee. She received a B.S. from Neuman College.
Ms. Henwood has served as a member of MAP Pharmaceuticals' Board of Directors since June 2004. Ms. Henwood is currently the President of Malvern Consulting Group, an independent pharmaceuticals, biologics and medical devices consulting firm, and serves as the Chief Executive Officer of RecroPharma, Inc., and Garnet BioTherapeutics, Inc. From 1999 to July 2006, Ms. Henwood was President, Chief Executive Officer, and, until May 2005, Chair of the Board of Auxilium Pharmaceuticals, Inc., which she also founded. From 1985 to 1999, Ms. Henwood served as President and Chief Executive Officer of IBAH, Inc., which she had also originally founded as Bio-Pharm Clinical Services, Inc. Ms. Henwood is a member of the board of directors of Alkermes, Inc., and serves as a member of its nominating and governance committee. She received a B.S. from Neuman College.
Merck and Co. (Retired)
Mr. Kelley has served as a member of MAP Pharmaceuticals' Board of Directors since May 2007. From 1993 to 2002, Mr. Kelley was President of the Merck Manufacturing Division, a division of Merck & Co., Inc., and served as a member of the Merck Management Committee from 1995 to 2002. He currently serves on the board of directors of Codexis, Inc., as well as Codexis' audit and compensation committees. Mr. Kelley received a B.S. in engineering from the U.S. Naval Academy.
Mr. Kelley has served as a member of MAP Pharmaceuticals' Board of Directors since May 2007. From 1993 to 2002, Mr. Kelley was President of the Merck Manufacturing Division, a division of Merck & Co., Inc., and served as a member of the Merck Management Committee from 1995 to 2002. He currently serves on the board of directors of Codexis, Inc., as well as Codexis' audit and compensation committees. Mr. Kelley received a B.S. in engineering from the U.S. Naval Academy.
Brookside Capital
Mr. McPherron has served as a member of MAP Pharmaceuticals' Board of Directors since January 2006. Since 1998, Mr. McPherron has been employed by Brookside Capital, LLC, an investment fund, where he is currently a Managing Director. From 1997 to 1998, Mr. McPherron served as President and Chief Operating Officer for U.S. Carelink, Inc. Mr. McPherron received an M.B.A. from Harvard Business School and a B.S. from the University of Kansas.
Mr. McPherron has served as a member of MAP Pharmaceuticals' Board of Directors since January 2006. Since 1998, Mr. McPherron has been employed by Brookside Capital, LLC, an investment fund, where he is currently a Managing Director. From 1997 to 1998, Mr. McPherron served as President and Chief Operating Officer for U.S. Carelink, Inc. Mr. McPherron received an M.B.A. from Harvard Business School and a B.S. from the University of Kansas.
MAP Pharmaceuticals
Mr. Nelson has served as MAP Pharmaceuticals' President and Chief Executive Officer and as a member of the Board of Directors since April 2005. As President and Chief Executive Officer, Mr. Nelson brings to the Board of Directors operating experience with the Company and insight into all aspects of the business. From 1998 to 2005, Mr. Nelson served as Senior Vice President of Commercial and Business Development at DURECT Corporation. From 1992 to 1998, Mr. Nelson held various senior management positions with Medtronic, including Business Director of the Neurological Division for Europe, the Middle East and Africa, from 1996 to 1998. Mr. Nelson received an M.M. with distinction from the Kellogg School of Management at Northwestern University and a B.S. in chemical engineering from the University of Minnesota.
Mr. Nelson has served as MAP Pharmaceuticals' President and Chief Executive Officer and as a member of the Board of Directors since April 2005. As President and Chief Executive Officer, Mr. Nelson brings to the Board of Directors operating experience with the Company and insight into all aspects of the business. From 1998 to 2005, Mr. Nelson served as Senior Vice President of Commercial and Business Development at DURECT Corporation. From 1992 to 1998, Mr. Nelson held various senior management positions with Medtronic, including Business Director of the Neurological Division for Europe, the Middle East and Africa, from 1996 to 1998. Mr. Nelson received an M.M. with distinction from the Kellogg School of Management at Northwestern University and a B.S. in chemical engineering from the University of Minnesota.
Sepracor (Retired)
Mr. O' Shea has served as a member of MAP Pharmaceuticals' Board of Directors since January 2012. Mr. O'Shea spent eight years at Sepracor where he held various roles in operations and commercialization, most recently as Vice Chairman. From October 1999 to March 2007, Mr. O'Shea was President and Chief Operating Officer at Sepracor. Prior to Sepracor, Mr. O'Shea was Senior Vice President of Sales and Marketing and Medical Affairs for Zeneca Pharmaceuticals, a business unit of Astra Zeneca Plc. While at Zeneca, he also held several management positions of increasing responsibility in international sales and marketing. Mr. O'Shea is past Chairman of the National Pharmaceutical Council and is also a board member of various healthcare and biopharmaceutical companies. Mr. O'Shea is a graduate of Liverpool Lord Byron University, where he received an honors degree in applied physics from the Institute of Physics.
Mr. O' Shea has served as a member of MAP Pharmaceuticals' Board of Directors since January 2012. Mr. O'Shea spent eight years at Sepracor where he held various roles in operations and commercialization, most recently as Vice Chairman. From October 1999 to March 2007, Mr. O'Shea was President and Chief Operating Officer at Sepracor. Prior to Sepracor, Mr. O'Shea was Senior Vice President of Sales and Marketing and Medical Affairs for Zeneca Pharmaceuticals, a business unit of Astra Zeneca Plc. While at Zeneca, he also held several management positions of increasing responsibility in international sales and marketing. Mr. O'Shea is past Chairman of the National Pharmaceutical Council and is also a board member of various healthcare and biopharmaceutical companies. Mr. O'Shea is a graduate of Liverpool Lord Byron University, where he received an honors degree in applied physics from the Institute of Physics.
Sangamo BioSciences
Mr. Wolff has served as a member of MAP Pharmaceuticals' Board of Directors since March 2008. Since December 2007, Mr. Wolff has been employed as Executive Vice President and Chief Financial Officer of Sangamo BioSciences, Inc. Mr. Wolff was formerly with Nuvelo, Inc., where he served as Senior Vice President, Finance and Chief Financial Officer from July 2006 until its restructuring in August 2007. Prior to joining Nuvelo, he was Senior Vice President, Finance and Chief Financial Officer of Abgenix, Inc., from September 2004 until April 2006, when Abgenix merged with Amgen Inc. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including as Senior Vice President and Chief Financial Officer of DoubleTwist, Inc. Mr. Wolff is a member of the board of directors at a private biopharmaceutical company and served as a member of the board of directors of Sangamo BioSciences, Inc. from June 2006 to December 2007, serving as chair of the audit committee. He began his career with Price Waterhouse, where he held a number of positions, including Senior Audit Manager. Mr. Wolff received an M.B.A. from Harvard Business School and a B.A. in economics from the University of California, Berkeley.
Mr. Wolff has served as a member of MAP Pharmaceuticals' Board of Directors since March 2008. Since December 2007, Mr. Wolff has been employed as Executive Vice President and Chief Financial Officer of Sangamo BioSciences, Inc. Mr. Wolff was formerly with Nuvelo, Inc., where he served as Senior Vice President, Finance and Chief Financial Officer from July 2006 until its restructuring in August 2007. Prior to joining Nuvelo, he was Senior Vice President, Finance and Chief Financial Officer of Abgenix, Inc., from September 2004 until April 2006, when Abgenix merged with Amgen Inc. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including as Senior Vice President and Chief Financial Officer of DoubleTwist, Inc. Mr. Wolff is a member of the board of directors at a private biopharmaceutical company and served as a member of the board of directors of Sangamo BioSciences, Inc. from June 2006 to December 2007, serving as chair of the audit committee. He began his career with Price Waterhouse, where he held a number of positions, including Senior Audit Manager. Mr. Wolff received an M.B.A. from Harvard Business School and a B.A. in economics from the University of California, Berkeley.
